TORONTO– Eli Lilly Canada today announced topline results from the SURMOUNT-5 Phase 3b open-label randomized clinical trial. Tirzepatide provided a 47% greater relative weight loss compared to Wegovy® (semaglutide). On average, tirzepatide led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. At 72 weeks, tirzepatide was superior to Wegovy on both the primary endpoint and all five …
London – Researchers found in their new study, published in the New England Journal of Medicine, that Ozempic or Wegovy, drug used for weight loss — semaglutide — might contribute to reducing or completely cutting the insulin shots in people diagnosed with Type 1 diabetes. They analysed information from 10 people with Type 1 diabetes who took the drug. who …
London – Researchers say weight loss medicines Ozempic and Wegovy by Novo Nordisk, may allow obese people get amazing results but they are not safe. These weight loss medicines carry lean mass that includes an individual’s bones, organs, and muscle — more than actual fat which can prove to be troublesome for one’s body.
